Heron Therapeutics, Inc. (HRTX)
NASDAQ: HRTX · Real-Time Price · USD
1.085
-0.035 (-3.12%)
Nov 21, 2024, 1:40 PM EST - Market open
Heron Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 137.74 | 127.04 | 107.67 | 86.35 | 88.64 | 145.97 | Upgrade
|
| Revenue Growth (YoY) | 12.13% | 17.99% | 24.70% | -2.59% | -39.28% | 88.41% | Upgrade
|
| Cost of Revenue | 72.38 | 117 | 158.18 | 175.64 | 209.52 | 229 | Upgrade
|
| Gross Profit | 65.36 | 10.04 | -50.51 | -89.3 | -120.88 | -83.03 | Upgrade
|
| Selling, General & Admin | 73.68 | 103.06 | 118.75 | 127.13 | 101.68 | 127.66 | Upgrade
|
| Operating Expenses | 73.68 | 103.06 | 118.75 | 127.13 | 101.68 | 127.66 | Upgrade
|
| Operating Income | -8.32 | -93.02 | -169.26 | -216.43 | -222.56 | -210.69 | Upgrade
|
| Interest Expense | -4.77 | -3.87 | -2.47 | -2.41 | -1.9 | -1.47 | Upgrade
|
| Interest & Investment Income | 3.36 | 3.36 | 1.64 | 0.43 | 3.63 | 7.26 | Upgrade
|
| Other Non Operating Income (Expenses) | 2.48 | 1.18 | -6.32 | -0.4 | - | 0.26 | Upgrade
|
| EBT Excluding Unusual Items | -7.25 | -92.34 | -176.42 | -218.81 | -220.83 | -204.65 | Upgrade
|
| Merger & Restructuring Charges | -4.2 | -4.2 | -5.4 | -1.4 | -5.6 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -0 | -0 | - | - | - | 0.01 | Upgrade
|
| Asset Writedown | -3.12 | -0.62 | -0.21 | -0.48 | -0.85 | -0.11 | Upgrade
|
| Other Unusual Items | -13.4 | -13.4 | - | - | - | - | Upgrade
|
| Pretax Income | -27.97 | -110.56 | -182.02 | -220.68 | -227.28 | -204.75 | Upgrade
|
| Net Income | -27.97 | -110.56 | -182.02 | -220.68 | -227.28 | -204.75 | Upgrade
|
| Net Income to Common | -27.97 | -110.56 | -182.02 | -220.68 | -227.28 | -204.75 | Upgrade
|
| Shares Outstanding (Basic) | 152 | 138 | 109 | 98 | 91 | 82 | Upgrade
|
| Shares Outstanding (Diluted) | 152 | 138 | 109 | 98 | 91 | 82 | Upgrade
|
| Shares Change (YoY) | 16.83% | 26.87% | 10.57% | 8.48% | 11.00% | 11.73% | Upgrade
|
| EPS (Basic) | -0.18 | -0.80 | -1.67 | -2.24 | -2.50 | -2.50 | Upgrade
|
| EPS (Diluted) | -0.18 | -0.80 | -1.67 | -2.24 | -2.50 | -2.50 | Upgrade
|
| Free Cash Flow | -9.61 | -60.33 | -148.74 | -206.38 | -191.63 | -131.73 | Upgrade
|
| Free Cash Flow Per Share | -0.06 | -0.44 | -1.37 | -2.10 | -2.11 | -1.61 | Upgrade
|
| Gross Margin | 47.45% | 7.90% | -46.91% | -103.42% | -136.38% | -56.88% | Upgrade
|
| Operating Margin | -6.04% | -73.21% | -157.20% | -250.65% | -251.09% | -144.34% | Upgrade
|
| Profit Margin | -20.30% | -87.02% | -169.05% | -255.58% | -256.41% | -140.27% | Upgrade
|
| Free Cash Flow Margin | -6.98% | -47.49% | -138.14% | -239.01% | -216.20% | -90.25% | Upgrade
|
| EBITDA | -5.7 | -90.12 | -166.37 | -213.41 | -219.72 | -208.65 | Upgrade
|
| EBITDA Margin | -4.13% | -70.93% | -154.51% | -247.15% | -247.88% | -142.94% | Upgrade
|
| D&A For EBITDA | 2.63 | 2.9 | 2.89 | 3.02 | 2.85 | 2.04 | Upgrade
|
| EBIT | -8.32 | -93.02 | -169.26 | -216.43 | -222.56 | -210.69 | Upgrade
|
| EBIT Margin | -6.04% | -73.21% | -157.20% | -250.65% | -251.09% | -144.34% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.